within Pharmacolibrary.Drugs.ATC.L;

model L04AX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 14.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 801 / 1000000,
    adminCount     = 1,
    Vd             = 0.0592,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01115,
    Tlag           = 17.4
  );

  annotation(Documentation(
    info ="<html><body><p>Pirfenidone is an orally administered antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF). It exhibits antifibrotic, anti-inflammatory, and antioxidant properties. Pirfenidone is approved for clinical use in the treatment of IPF in multiple countries including the US, EU, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects (male and female, aged 18–55 years) after single-dose administration.</p><h4>References</h4><ol><li><p>Sgalla, G, et al., &amp; Richeldi, L (2023). BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF). <i>Expert opinion on investigational drugs</i> 32(1) 17–23. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2023.2173061&quot;>10.1080/13543784.2023.2173061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36693635/&quot;>https://pubmed.ncbi.nlm.nih.gov/36693635</a></p></li><li><p>Huang, NY, et al., &amp; Hua, WY (2013). Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. <i>Drug research</i> 63(8) 388–395. DOI:<a href=&quot;https://doi.org/10.1055/s-0033-1341478&quot;>10.1055/s-0033-1341478</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23580109/&quot;>https://pubmed.ncbi.nlm.nih.gov/23580109</a></p></li><li><p>Maher, TM, et al., &amp; Wuyts, W (2018). Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. <i>The Lancet. Respiratory medicine</i> 6(8) 627–635. DOI:<a href=&quot;https://doi.org/10.1016/S2213-2600(18)30181-4&quot;>10.1016/S2213-2600(18)30181-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29792287/&quot;>https://pubmed.ncbi.nlm.nih.gov/29792287</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AX05;
